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Objectives: To evaluate veno-occlusive disease of the liver
(VOD) and non-hepatic regimen related toxicity (RRT) in patients
receiving allogeneic stem cell transplantation (allo-SCT) after con-
ditioning with BUCY plus thiotepa, using an intravenous (IV)
formulation of busulfan. Patients and Methods: Twenty-six adult
patients (20 men and 6 women; median age 32 years) underwent
allo-SCT between 2002 and 2004 after conditioning with thiotepa
(10 mg/kg), CY (120 mg/kg) and IV BU (9.6 mg/kg). Fourteen
patients received anti-thymocyte globulin (ATG). Diagnoses were
acute leukemia or myelodysplastic syndrome (20 patients), chronic
myeloid leukemia (3 patients) and other diseases (3 patients). Ten
patients received grafts from HLA-identical siblings and 16 from
alternative donors (cord blood in 12 cases). GVHD prophylaxis
consisted of cyclosporin A (CsA) and prednisone in 16 cases, CsA
and methotrexate in 9 and CsA alone in 1. VOD and non-hepatic
RRT were assessed according to Baltimore and Bearman criteria,
respectively. Results were compared to 53 historical controls who
underwent allo-SCT between 1997 and 2004 using the same con-
ditioning regimen but giving oral BU (12 mg/kg) instead of IV BU.
Results: Four of 26 patients (15%) developed VOD which was
resolved before day 100 after transplant in all cases. Severe VOD
was not observed. Signiﬁcant increases (more than 2 fold) in AST
and total bilirubin levels were observed in 19 patients (73%). The
median maximum levels of AST and total bilirubin were 72 U/L
and 2 mg/dL, respectively. Sixteen patients (62%) developed non-
hepatic RRT that was greater than grade 1 in 13 cases (50%). The
VOD rate was not signiﬁcantly different when comparing patients
receiving IV BU and oral BU (15% vs. 6%; P  0.2). However,
non-hepatic RRT was more frequent among patients receiving oral
BU (92% vs. 61%; P .002), with a higher toxicity rate of grade 2 or
more (76% vs. 50%; P  0.02). No differences were found between
the two groups regarding the underlying disease, type of transplant,
age of patients and use of ATG. MTX was more commonly used in
patients receiving IV BU (35% vs. 15%; P  0.05). Conclusions:
The use of IV BU seems to reduce non-hepatic toxicity after condi-
tioning with BUCY plus thiotepa for allo-SCT.
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LESS TRANSPLANT-RELATED MORTALITY WITH VARIABLE INTENSITY
CONDITIONING THAN NON-MYELOABLATIVE CONDITIONING IN UNRE-
LATED AND RELATED ADULT ALLOGENEIC TRANSPLANT RECIPIENTS
Bigelow, C.L.; Elkins, S.; Hardy, C.L.; Files, J.C. University of Mis-
sissippi Medical Center, Jackson, MS.
For the past four years, our adult allogeneic transplant program
has employed two alternative approaches to standard recipient
conditioning, the use of non-myeloablative “mini” conditioning
and variable intensity conditioning. We now report a retrospective
comparison of relapse, day 100 and one-year survival, engraft-
ment and grades I-II and III-IV acute GVHD in unrelated as well
as related recipients in these two preparative regimen groups.
Patients with a variety of malignancies were not randomized to
receive either non-myeloablative (Group 1) or variable intensity
(Group 2) conditioning. Twenty patients with a median age of 49
(range 27–64, Group 1) and 18 patients also with a median age of
49 (range 24–58, Group 2) received either marrow or peripheral
blood stem cells, usually with a 6/6 match grade. One recipient in
Group 2 received a cord blood transplant (4/6 match). Group 1
regimen consisted of four protocols: ﬂudarabine 30 mg/m2  3 d
and TBI 200 cGY; ﬂudarabine  6 d, busulfan 4 mg/kg  2 d and
ATG 40 mg/kg 4 d; ﬂudarabine 5 d and cyclophosphamide 60
mg/kg  2 d; ﬂudarabine, cyclophosphamide, ATG. Group 2
regimen consisted of Campath 20 mg/d either 5 or 3 days, ﬂudara-
bine  5 d and melphalan 140 mg/m2  1 d. GVHD prophylaxis
was the same in both groups (standard dose cyclosporine or ta-
crolimus and MMF.) All patients received an adequate CD34 cell
dose and none of the products was manipulated. Relapse rate was
16% in Group 1 and 33% in Group 2. Day 100 survival and
one-year survival were 55% and 25%, respectively, in Group 1 vs
69% and 42% in Group 2. Only one patient in Group 2 had acute
GVHD, grades I-II; none had grades III-IV. However, in Group 1,
6 patients had grades I-II and 7 had grades III-IV (39%). Graft
failure occurred in four patients in Group 1, while no patients in
Group 2 experienced it. We conclude, ﬁrst, that in our program
the application of variable intensity conditioning has been quite
successful in unrelated transplant recipients, as well as in related.
Second, signiﬁcant treatment related mortality in the form of graft
failure and acute GVHD occurred less frequently in recipients who
received this conditioning than in those receiving non-myeloabla-
tive conditioning. This regimen requires some modiﬁcation to
enhance its tumoricidal properties; however, its treatment-related
toxicity is minimal and allows us to offer this therapy to patients
with co-morbid conditions and older age.
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REPLACEMENT DONOR PROGRAM: MORE THAN PROTECTING STEM
CELL DONORS FROM MULTIPLE DONATIONS FOR DIFFERENT PA-
TIENTS
Baier, D.M.; Gawellek, A.; Rutt, C. DKMS Deutsche Knochenmark-
spenderdatei gGmbH, Tuebingen, Germany.
Goal of DKMS’ Replacement Donor Program is to provide an
alternative donor for search centers in case that a donor has
completed a stem cell donation and is reserved for potential further
donations for the same patient for 2 years. First intention is to
provide a donor as long as possible for “his” patient afterwards the
2 year suspension. This would enable us to provide second or
further stem cell donations if required for the one patient. Second
intention is to protect the donor from requests for multiple pa-
tients. It could be observed several times that post-donation donors
were of increased interest for search centers and were requested for
conﬁrmatory typing (CT) several times. Providing alternative do-
nors would take off the burden from a single donor. Third inten-
tion is to ﬁll up the gap in HLA-phenotypes when a donor is
suspended from further donations for 2 years after donation and to
increase the number of high resolution typed donors at DKMS.
We think that donor centers like the DKMS have the responsibil-
ity to protect their donors from excessive demand by search cen-
ters. Forth intention is to provide an alternative donor for donors
in actual workups in case that the donor in workup is unavailable
for unpredictable reasons. As the search for the Replacement Do-
nor starts with initiation of the workup it is very important that the
full HLA-phenotype of the patient is available as early as possible.
We perform up to 100 DRB1* intermediate resolution or up to 5
DRB*/DQB1* high resolution typings with IDMs (CMV) on our
own behalf for each donor at initiation of workup per own search
to ﬁnd a Replacement Donor. Own searches are repeated two
times. Until October 2004, over 87000 HLA-DRB1* typings on
intermediate and 8600 high resolution typings of HLA-DRB* and
HLA-DQB1* were performed to provide Replacement Donors for
more than 3200 donors. Replacement Donors could be found for
994 donors to date. We could not only ﬁnd Replacement Donors
but also improved the quality of our database. This is shown by the
fact that over 3900 further requests (high resolution typing or
conﬁrmatory typing) and 340 workups could be observed out of the
over 95000 “prospective” typings. Only a few (7) stem cell donors
donated again for another patient since start of the project. In 5
cases a Replacement Donor could replace an unavailable donor
while the workup was still in process. (DKMS performed over 3900
donations since start of this project in 2001.)
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LONG-TERM OUTCOME AFTER MARROW TRANSPLANTATION FROM
HLA-IDENTICAL SIBLING DONORS FOR ACQUIRED APLASTIC ANAEMIA
USING CYCLOPHOSPHAMIDE AND IN-VIVO ANTI-CD52 MONOCLONAL
ANTIBODIES
Gupta, V.1; Ball, S.E.1; Yi, Q.-L.2; Sage, D.3; McCann, S.R.4; Lawler,
M.4; Ortin, M.1; Freires, M.1; Hale, G.5; Waldmann, H.5; Gordon-
Smith, E.C.1; Marsh, J.C.W.1 1. Department of Haematology, St.
George’s Hospital and Medical School, London, United Kingdom; 2.
Department of Biostatistics, Princess Margaret Hospital, Toronto, Can-
ada; 3. National Blood Service, London, United Kingdom; 4. John
Durkan Leukemia Research Laboratory, St. James Hospital, Dublin,
Ireland; 5. Sir William Dunn School of Pathology, Oxford University,
Oxford, United Kingdom.
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Despite excellent survival of marrow transplantation (BMT) in
acquired severe aplastic anemia (SAA) using sibling donors, graft-
versus-host disease (GVHD) continues to remain a major problem
resulting in long-term complications and impaired quality of life.
Between Aug 1989 and Aug 2004, 35 patients at our centre with
acquired SAA underwent BMT from HLA-identical sibling donors
using cyclophosphamide (CY) 50 mg/kg  4 (days 5 to 2) and
anti-CD52 MoAb 0.75–1 mg/kg BW as conditioning. Prior to
1999, rat derived anti-CD52 MoAb (Campath-1G) was used. We
switched to humanised version of anti-CD52 MoAb (Alemtu-
zumab) when it became available in 1999. Median age at BMT was
17 yrs (range 4–46). Prior to BMT, 58% were heavily transfused
(50 transfusions) and 42% had previously failed ATG. Unma-
nipulated bone marrow was used as source of stem cells in all
except one. GVHD prophylaxis was with cyclosporine (CSA) alone
in 21 (60%) patients; 14 received anti-CD52 MoAb in addition to
CSA. Eight patients had graft failure (primary, 4; secondary, 4)
with a cumulative incidence of 23%. Graft failure was non-signif-
icantly higher in those receiving CSA and anti-CD52 MoAb as
GVHD prophylaxis. No cases of graft failure are seen in 10 pa-
tients treated after 1999. The cumulative incidence of acute grade
II-IV GVHD and chronic GVHD was 13% and 4%, respectively.
None developed extensive chronic GVHD. Of the 19 recipients
positive for cytomegalovirus (CMV), reactivation was seen in 5
(26%) with in 100 days. No cases of late CMV reactivation were
observed. Six patients died of complications related to BMT at a
median of 248 days (range 47–414). With a median follow-up of 59
months, the 5-year survival was 83% (95% C.I. 68–96). There was
a non-signiﬁcant trend towards improved survival in patients trans-
planted after 1995 (94% vs. 74%). Of the 29 survivors, serial
chimerism studies were available on 20 and showed: 100% donor
cells, 15; stable mixed chimerism with 85% donor cells, 3; and
autologous recovery, 2. All survivors are transfusion-independent
and have performance status of 100% except one who developed
avascular necrosis. We conclude that the conditioning regimen
containing CY and anti-CD52 MoAb is well tolerated and efﬁca-
cious for acquired SAA using HLA-matched sibling donors. Based
on the encouraging results of our study, further investigations are
in progress evaluating the role of Alemtuzumab in the transplant
protocols for AA using CSA alone as GVHD prophylaxis.
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IN VIVO SPATIAL AND TEMPORAL ANALYSES IN MICE REVEAL REDUN-
DANCY OF LYMPHOID TISSUES IN INDUCING ACUTE GVHD AFTER
ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
Beilhack, A.1; Schulz, S.1; Baker, J.1; Beilhack, G.F.1; Wieland, C.B.1;
Baker, E.M.1; Herman, E.I.1; Landan, G.1; Olson, J.A.1; Cao, Y.-A.2;
Contag, C.H.2; Negrin, R.S.2 1. Department of Medicine, Division of
BMT, Stanford University, Stanford, CA; 2. Department of Pediatrics,
Stanford University, Stanford, CA. (A.B. and S.S. contributed equally to
this work.)
Allogeneic hematopoietic cell transplantation is an effective ther-
apy for the treatment of malignant and non-malignant disorders,
and yet graft-versus-host disease (GVHD) remains a major obsta-
cle. Given the dynamic changes in immune cell subsets and tissue
organization, which occur in GVHD, localization and timing of
critical immunological events in vivo may reveal basic pathogenic
mechanisms of GVHD. We transplanted light-emitting luciferase
transgenic allogeneic splenocytes, and non-invasively monitored
their tissue distribution in living mice with major histocompatibil-
ity differences. Bioluminescence images were used to guide tissue
selection for high-resolution analyses of cell subsets and tissue
distribution. We demonstrated the sequential inﬁltration of lymph
nodes, Peyers patches and spleen by donor derived CD4 T cells
initially, followed by CD8 T cells, and an evolution of homing
receptors that correlated with patterns of cell distribution. These
data underline the important role of secondary lymphoid organs as
sites for GVHD initiation. To determine whether there are in-
structive priming sites for speciﬁc cell migration to GVHD target
organs such as gut, liver and skin we selectively interfered with the
migration of donor T cells to lymphoid organs by administration
of blocking antibodies to L-selectin and MAdCAM-1. Treated
allogeneic recipients interfered with entry of allogeneic splenocytes
into some secondary lymphoid tissues yet still developed GVHD.
Similarly, allogeneic Peyer’s patch deﬁcient recipients manifested
intestinal disease and succumbed to GVHD. These animals were
generated by treatment with lymphotoxin-alpha-IgG fusion pro-
tein during embryonic development. In vivo imaging and detailed
cellular analysis showed that remaining lymphoid tissues compen-
sated for the lack of others. Of importance, T cells that lacked
homing molecules for secondary lymphoid organs had alloreactive
properties in vitro, yet did not cause GVHD in vivo. Transplan-
tation of T cells with deﬁned homing properties therefore appears
to be a promising alternative in conferring protective immunity
early after HCT without the risk of GVHD.
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CHOOSING THE PATIENT FOR AMBULATORY STEM CELL TRANSPLAN-
TATION
Cantu-Rodriguez, O.G.; Gutierrez-Aguirre, C.H.; Gonzalez-LLano,
O.; Jaime-Perez, J.C.; Salazar-Riojas, R.; Martinez-Gonzalez, O.L.;
Gomez-Almaguer, D. Hospital Universitario Dr. Jose E. Gonzalez,
Monterrey, Nuevo Leon, Mexico.
Introduction: Allogeneic non-myeloablative stem cell transplan-
tation has been shown to reduce systemic toxicity and make pos-
sible the procedure in an ambulatory setting. Objective: To de-
scribe the characteristics of patients selected for an ambulatory
stem cell transplant based on a non-myeloablative chemotherapeu-
tic scheme. Material and Methods: Forty one patients were in-
cluded (26 males and 15 females) with the following diagnoses:
CML (12), CLL (2), ALL (5), AML (10), NHL (3), HL (1), MDS
(3), AA (2), MM (1) and renal cell adenocarcinoma (1). Ages ranged
between 8 and 61 years, with a mean of 36 years. Karnofsky scores
in all patients were superior to 80. All patients tolerated oral
feeding. Hemoglobin values ranged between 6.8 and 15.8 g/dl with
a mean of 12 g/dl. Platelet counts ranged between 14.4  109/L
and 1,200  109/L with a mean of 207.8  109/L. Serum creati-
nine ranged between 0.54 and 2 mg/dL with a mean of 0.9 mg/dL.
Results: Twenty patients completed the transplant on a fully
ambulatory setting basis. All had a Karnofsky scale value of 100.
Mean values were 13 g/dl (hemoglobin), 218.5  109/L (platelets)
and 0.9 g/dL (serum creatinine). Twenty-one patients began the
transplant procedure on an ambulatory basis, but eventually re-
quired admission because of fever and/or mucositis (inpatient days
ranged from 4 to 24 days). Karnofsky scores in these patients
ranged between 80 and 100. Mean values from these patients were
10.9 g/dl (hemoglobin), 195.7  109/L (platelets) and 0.93 mg/dL
(serum creatinine). Conclusions: Half of the patients admitted to
the study completed successfully their stem cell transplantation
procedure on an ambulatory setting. Factors related to this out-
come were normal hematological values after the transplant and
Karnofsky scores  80. These values could predict with a high
degree of probability whether or not a stem cell transplantation
could be successfully performed in an ambulatory setting.
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THE HEMATOPOIETIC CELL TRANSPLANTATION DATABASE AT DBMHC
Helmberg, W.1; Malkki, M.2; Feolo, M.1; Hoffman, D.1; Petersdorf, E.2
1. NCBI, Bethesda, MD; 2. Fred Hutchinson Cancer Research Institute,
Seattle, WA.
The dbMHC www.ncbi.nih.gov/mhc is a public resource for the
storage, display and analysis of MHC related genotype and clinical
data. This resource has been developed at National Center for
Bioinformatics (NCBI) through collaboration with the Interna-
tional Histocompatibility Working Group (IHWG). One module
provides public access to data of the Hematopoietic Cell Trans-
plantation project (HCT) of the IHWG. The HCT section of
dbMHC is intended to serve the unmet need of the research and
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